干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
中源协和

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 28214|回复: 0
go

[已解决求助] 求助文献一篇,非常感谢! [复制链接]

Rank: 2

积分
108 
威望
108  
包包
35  
楼主
发表于 2017-6-16 10:08 |显示全部帖子 |倒序浏览 |打印
干细胞之家微信公众号
Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.
# h  W4 b! |" F  U3 |/ W* B- {7 y" n; S- U$ p3 f+ r/ T* I9 X- c$ g
Koutsilieris M1, Sourla A, Pelletier G, Doillon CJ.* m# N) C* R+ O- j# P7 m
Author information
0 ]6 R6 P+ f; a& J$ B* RAbstract* d; D8 n: e: C* ^$ h& e( E/ @$ t
We developed a three-dimensional type I collagen gel cell culture system that allows coculturing of human MG-63 osteoblast-like cells and various human cancer cells. Inoculation of human PC-3 metastatic prostate cancer cells into this type I collagen gel containing human MG-63 osteoblast-like cells produced an osteoblastic-like reaction that presented as an increased number of MG-63 cells and increased density of type I collagen around MG-63 cells adjacent to inoculated PC-3 cells by microscope analysis. Under identical experimental conditions, inoculation of cell-free medium, human KLE endometrial adenocarcinoma cells, and Calu-1 lung cancer cells did not produce this blastic-like reaction. In situ hybridization documented the uniform expression of insulin-like growth factor I (IGF-I) and of urokinase-type plasminogen activator (uPA) mRNA in MG-63 and PC-3 cells separately cultured in this substrata. The uniform expression of uPA was also documented by immunocytochemistry using a monoclonal and a polyclonal antihuman uPA antibody. The relative expression of uPA was higher in PC-3 cells than in MG-63, KLE, and Calu-1 cancer cells. We conclude that this novel cell culture system may become a useful model to study the pathophysiology of the osteoblastic reaction in vitro.
" [; d  ^3 h0 x  n* e" o! g- T9 xPMID: 7863832 DOI: 10.1002/jbmr.5650091120
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2026-6-29 04:17

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.